Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury

Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.